ES2134709A1 - Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m - Google Patents

Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m

Info

Publication number
ES2134709A1
ES2134709A1 ES09602700A ES9602700A ES2134709A1 ES 2134709 A1 ES2134709 A1 ES 2134709A1 ES 09602700 A ES09602700 A ES 09602700A ES 9602700 A ES9602700 A ES 9602700A ES 2134709 A1 ES2134709 A1 ES 2134709A1
Authority
ES
Spain
Prior art keywords
emesa
troubles
treatment
obsessive compulsive
sexual dysfunctions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09602700A
Other languages
English (en)
Other versions
ES2134709B1 (es
Inventor
Constansa Jordi Frigola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2134709A1 publication Critical patent/ES2134709A1/es
Application granted granted Critical
Publication of ES2134709B1 publication Critical patent/ES2134709B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Utilización de los derivados de 1- 4-[4-abril (o heteroaril)-1-piperazinil]-butil -1h-azol para la preparación de un medicamento destinado al tratamiento de los trastornos obsesivo-compulsivos de la apnea del sueño, de las disfunciones sexuales de la emesis del mareo en los mamíferos, incluido el hombre. La invención se refiere a la utilización de derivados de 1- 4-[4-aril o heteroaril)-1-piperazinil]-butil -1H-azol así como de sus sales fisiológicamente aceptables, para la fabricación de medicamentos destinados al tratamiento de los trastornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo.
ES009602700A 1995-12-12 1996-12-12 Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m Expired - Lifetime ES2134709B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514690A FR2742052B1 (fr) 1995-12-12 1995-12-12 Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports

Publications (2)

Publication Number Publication Date
ES2134709A1 true ES2134709A1 (es) 1999-10-01
ES2134709B1 ES2134709B1 (es) 2000-05-16

Family

ID=9485400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009602700A Expired - Lifetime ES2134709B1 (es) 1995-12-12 1996-12-12 Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m

Country Status (16)

Country Link
EP (1) EP0808166A1 (es)
JP (1) JPH11501051A (es)
CN (1) CN1177297A (es)
AR (1) AR004378A1 (es)
AU (1) AU716665B2 (es)
CA (1) CA2211161A1 (es)
CZ (1) CZ255197A3 (es)
ES (1) ES2134709B1 (es)
FR (1) FR2742052B1 (es)
HU (1) HUP9800198A2 (es)
IL (1) IL121461A0 (es)
NO (1) NO973589L (es)
PL (1) PL321779A1 (es)
TR (1) TR199700794T1 (es)
WO (1) WO1997021439A1 (es)
ZA (1) ZA9610457B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763950B1 (fr) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
WO2002014317A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
AU2001286454B2 (en) 2000-08-14 2006-09-14 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
JP5140225B2 (ja) 2000-08-14 2013-02-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
US7795266B2 (en) 2003-09-25 2010-09-14 Helton David R Tetrahydroindolone derivatives for treament of neurological conditions
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
DE602006012650D1 (de) 2005-04-26 2010-04-15 Hypnion Inc Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
BRPI0610258A2 (pt) 2005-04-26 2012-09-25 Hypnion Inc composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
GB2435827A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
CN115304590B (zh) * 2022-09-19 2024-05-28 皮摩尔新药(辽宁)有限公司 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497659A1 (fr) * 1991-01-28 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497659A1 (fr) * 1991-01-28 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Br. Journal Pharmacol., Vol. 113, no 2, 1994, paginas 425-430. M. BALLARIN "Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover". *

Also Published As

Publication number Publication date
AU716665B2 (en) 2000-03-02
HUP9800198A2 (hu) 1999-09-28
AU1376497A (en) 1997-07-03
TR199700794T1 (xx) 1997-11-21
CN1177297A (zh) 1998-03-25
ES2134709B1 (es) 2000-05-16
NO973589D0 (no) 1997-08-04
CZ255197A3 (cs) 1998-01-14
AR004378A1 (es) 1998-11-04
CA2211161A1 (fr) 1997-06-19
IL121461A0 (en) 1998-02-08
EP0808166A1 (fr) 1997-11-26
ZA9610457B (en) 1997-06-24
FR2742052B1 (fr) 1998-04-10
WO1997021439A1 (fr) 1997-06-19
PL321779A1 (en) 1997-12-22
NO973589L (no) 1997-10-08
JPH11501051A (ja) 1999-01-26
MX9706133A (es) 1997-11-29
FR2742052A1 (fr) 1997-06-13

Similar Documents

Publication Publication Date Title
MXPA03007712A (es) Sales farmaceuticas.
ES2134709A1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
CA2386690A1 (en) Pharmaceutical tramadol salts
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
RU95106639A (ru) Способ лечения бактериальной инфекции, применение азитромицина для получения лекарственной формы
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
DE69531098D1 (de) Piperidine und pyrrolidine
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2218917C2 (ru) Применение специфического антагониста 5ht2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
NO982989L (no) Anvendelse av inhibitorer av den cellulµre Na+/H+-utbytteren (NHE) for fremstilling av et medikament for respiratorstimulering
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
NO20015228L (no) Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BG105204A (en) Salts of paroxetine
PL371551A1 (en) Statin therapy for enhancing cognitive maintenance
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991001

Kind code of ref document: A1

Effective date: 19991001